Melanoma patients with BRAF mutation usually have a positive response to treatment with BRAF inhibitors, but nearly all of those patients develop resistance to the drugs and experience disease progression. Now, a new preclinical study published online ahead of print in the ia/i from Penn Medicine researchers found that in many cases the root of the resistance may lie in a never-before-seen autophagy mechanism induced by the BRAF inhibitors vermurafenib and ...
via Medindia Health News More READ
No comments:
Post a Comment